 "No permission given to hike drug prices beyond limits: Govt")
Government has not given nod to any pharma firm to increase prices of drugs beyond permissible limits, Parliament was informed on Tuesday.
"Few companies have given representations for increasing prices of medicines beyond permissible limits mentioning various reasons like increase in cost, tax, foreign exchange rates etc. However, no company has been given permission to increase the prices so far," Minister of Chemicals & Fertilisers and Parliamentary Affairs Ananth Kumar said in a reply to a question in the Lok Sabha.
The government has brought down the prices of 404 medicines under NLEM 2015 (revised schedule-I) of the Drug Price Control Order 2013, he added.
Earlier, "the government has reduced the ceiling prices of 530 medicines as on 2/3/2016 under NLEM 2011 of DPCO 2013 (original schedule-I) on the basis of negative wholesale price index (WPI)", Kumar said.
Schedule I of DPCO 2013 has the national list of essential medicines.
"Few companies have given representations for increasing prices of medicines beyond permissible limits mentioning various reasons like increase in cost, tax, foreign exchange rates etc. However, no company has been given permission to increase the prices so far," Minister of Chemicals & Fertilisers and Parliamentary Affairs Ananth Kumar said in a reply to a question in the Lok Sabha.
The government has brought down the prices of 404 medicines under NLEM 2015 (revised schedule-I) of the Drug Price Control Order 2013, he added.
Earlier, "the government has reduced the ceiling prices of 530 medicines as on 2/3/2016 under NLEM 2011 of DPCO 2013 (original schedule-I) on the basis of negative wholesale price index (WPI)", Kumar said.
Schedule I of DPCO 2013 has the national list of essential medicines.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%